

COPY

Practitioner's Docket No. MP198-052P1RDV10DV1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Acton, Susan L.

Application No.: TBA

Group No.: TBA

Filed: Herewith

Examiner: TBA

For: NOVEL PROTEIN KINASE MOLECULES AND USES THEREFOR

Mail Stop Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,
AND/OR AMENDMENT PERTAINING THERETO
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE

1. ☒ This submission accompanies the new application being filed concurrently herewith.
☐ This replies to the Office Letter Dated _____

☐ A copy of the Office Letter is enclosed.

IDENTIFICATION OF PERSON MAKING STATEMENT

2. I, Tracy M. Sioussat

(type or print name of person signing below)

state the following:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)


37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail.

- ☒ as "Express Mail Post Office to Addressee"
Mailing Label No. EV439625520US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.


Signature

Date: February 25, 2004Sean Hunziker

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Submission-Nucleotide and/or Amino Acid Sequence—Page 1 of 4)

BEST AVAILABLE COPY

Practitioner's Docket No. MPI98-052P1RDV10DV1M**ITEMS BEING SUBMITTED**

3. Submitted herewith is/are:

- A. ☒ "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.
- B. ☐ An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C. ☐ A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D. ☒ Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:	Acton, Susan L.		
Application No.:	09/757,982	Group No.:	1644
Filed:	January 10, 2001	Examiner:	Haddad, Maher M.
For:	NOVEL PROTEIN KINASE MILECULES AND USES THEREFOR		

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form	"Sequence Identifier"
(other application)	(this application)

- E. ☒ A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. Section 1.821(f).
- ☐ Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. Section 1.821(b).

(Submission: Nucleotide and/or Amino Acid Sequence--Page 2 of 4)

BEST AVAILABLE COPY

Practitioner's Docket No. MPI98-052P1RDV10DV1M

F. ☐ Because this submission is made in fulfilling the requirement under 37 C.F.R. Section 1.821(g), a statement that the submission includes no new matter.

☐ Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. Section 1.821(g).

**STATEMENT THAT "SEQUENCE LISTING"
AND COMPUTER READABLE COPY ARE THE SAME
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

4. I hereby state:

- A. ☒ Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. ☒ All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

EXTENSION OF TERM

5. The proceedings herein are for a patent application and the provisions of 37 C.F.R. Section 1.136 apply.

- (a) ☐ Applicant petitions for an extension of time under 37 C.F.R. Section 1.136 (fees: 37 C.F.R. Section 1.17(a)(1)-(4)) for the total number of months checked below:

Extension (months)	Fee for other than small entity	Fee for small entity
<input type="checkbox"/> one month	\$ 110.00	\$ 55.00
<input type="checkbox"/> two months	\$ 420.00	\$ 210.00
<input type="checkbox"/> three months	\$ 950.00	\$ 475.00
<input type="checkbox"/> four months	\$1,480.00	\$ 740.00

Fee \$0.00

If an additional extension of time is required, please consider this a petition therefor.

☐ An extension for _____ months has already been secured, and the fee paid therefor of \$0.00 is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$0.00

(Submission Nucleotide and/or Amino Acid Sequence—Page 3 of 4)

BEST AVAILABLE COPY

Practitioner's Docket No. MPI98-052P1RDV10DV1M

OR

- (b) ☒ Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

FEE PAYMENT

6. ☐ Attached is a check in the sum of \$ _____.

☐ Charge Account No. 501668 the sum of \$0.00
A duplicate of this transmittal is attached.

FEE DEFICIENCY

8. ☒ If any additional extension and/or fee is required, charge Account No. 501668

February 25, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By



Tracy M. Sioussat

Registration No. 50,609

40 Landsdowne Street

Cambridge, MA 02139

Telephone - (617) 374-7679

Facsimile - (617) 551-8820

(Submission Nucleotide and/or Amino Acid Sequence - Page 4 of 4)

BEST AVAILABLE COPY

SEP 22 2006

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

In re application of:	Susan L. Acton		
Application No.:	10/786,501	Group No.	1643
Filed:	February 25, 2004	Examiner:	Humphrey, David H.
For:	CARDIOVASCULAR SYSTEM ASSOCIATED PROTEIN KINASE 3 (CSAPK-3) ANTIBODIES (as amended)		

Practitioner's Docket No. MPI98-052P1RDV10DV1M

PATENT

Certificate of Transmission under 37 CFR 1.8

1-571-273-8300

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

on September 22, 2006

Signature

Ann Sherry

Typed or printed name of person signing Certificate

Submitted herewith:

This Certificate of Transmission under 37 CFR 1.8
Response Transmittal (in duplicate)
Amendment and Response
Copy of "Submission of Sequence Listing"

1 page
6 pages
11 pages
4 pages

Total Pages 22 pages
(including this cover sheet)

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

BEST AVAILABLE COPY

SEP 22 2006

Practitioner's Docket No. MPI98-052P1RDV10DV1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Susan L. Acton		
Application No.:	10/786,501	Group No.:	1643
Filed:	February 25, 2004	Examiner:	Humphrey, David H.
For:	CARDIOVASCULAR SYSTEM ASSOCIATED PROTEIN KINASE 3 (CSAPK-3) ANTIBODIES (as amended)		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Confirmation No. 3988

TRANSMITTAL

1. Transmitted herewith for this application is/are:
 - a. This Transmittal (3 pages – in duplicate);
 - b. Amendment (11 pages);
 - c. Copy of "Submission of Sequence Listing" (4 pages); and
 - d. Certificate of Transmission under 37 CFR 1.8 (1 page).

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee" Mailing Label No. _____

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office at 1-571 273 8300.

Signature

Ann Sherry

(type or print name of person certifying)

Date: September 22, 2006

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

09/25/2006 WASFAW1 00000010 501668 10786501

(Page 1 of 3)

01 FC:1251 120.00 DA

Practitioner's Docket No. MPI98-052P1RDV10DV1M

FEE DEFICIENCY

6. If any additional extension and/or fee is required, charge Account No. 501668.
If any additional fee for claims is required, charge Account No. 501668.
7. Correspondence Address
Direct all future correspondence to:

Customer Number 30405


OR

Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139

September 22, 2006

MILLENNIUM PHARMACEUTICALS, INC.

By


Mario Cloutier

Registration No. 57,225

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-577-3522

Facsimile - 617-551-8820

(Page 3 of 3)